Stock News

Pivot Point Capital Partners Increased Its Monro Muffler Brake (MNRO) Holding; Summit Therapeutics plc (SMMT) Had 5 Analysts Last Week

Pivot Point Capital Partners Llc increased Monro Muffler Brake Inc (MNRO) stake by 374.11% reported in 2017Q2 SEC filing. Pivot Point Capital Partners Llc acquired 176,438 shares as Monro Muffler Brake Inc (MNRO)’s stock declined 12.59%. The Pivot Point Capital Partners Llc holds 223,600 shares with $9.34M value, up from 47,162 last quarter. Monro Muffler Brake Inc now has $1.65 billion valuation. The stock decreased 0.30% or $0.15 during the last trading session, reaching $50.3. About 450,195 shares traded or 45.21% up from the average. Monro, Inc. (NASDAQ:MNRO) has declined 18.88% since December 3, 2016 and is downtrending. It has underperformed by 35.58% the S&P500.

Among 6 analysts covering Summit Therapeutic (NASDAQ:SMMT), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Summit Therapeutic had 9 analyst reports since August 19, 2015 according to SRatingsIntel. On Tuesday, June 21 the stock rating was initiated by Janney Capital with “Buy”. The firm earned “Buy” rating on Friday, September 16 by H.C. Wainwright. The rating was maintained by H.C. Wainwright on Thursday, July 6 with “Buy”. Zacks downgraded the stock to “Hold” rating in Tuesday, September 1 report. The stock has “Buy” rating by Oppenheimer on Thursday, June 22. The rating was reinitiated by H.C. Wainwright with “Buy” on Friday, December 1. As per Thursday, June 15, the company rating was maintained by Canaccord Genuity. RBC Capital Markets maintained Summit Therapeutics plc (NASDAQ:SMMT) rating on Wednesday, November 16. RBC Capital Markets has “Outperform” rating and $29 target. Oppenheimer maintained Summit Therapeutics plc (NASDAQ:SMMT) rating on Wednesday, August 19. Oppenheimer has “Buy” rating and $28 target. See Summit Therapeutics plc (NASDAQ:SMMT) latest ratings:

01/12/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $16 Reinitiate
06/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $26.0000 Maintain
22/06/2017 Broker: Oppenheimer Rating: Buy New Target: $24.0000 Maintain
15/06/2017 Broker: Canaccord Genuity Rating: Buy New Target: $28.0000 Maintain

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $164.29 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

The stock decreased 0.76% or $0.09 during the last trading session, reaching $11.68. About 7,506 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since December 3, 2016 and is uptrending. It has outperformed by 16.52% the S&P500.

Investors sentiment decreased to 1.22 in Q2 2017. Its down 0.23, from 1.45 in 2017Q1. It worsened, as 31 investors sold MNRO shares while 47 reduced holdings. 31 funds opened positions while 64 raised stakes. 33.30 million shares or 2.32% less from 34.09 million shares in 2017Q1 were reported. Eagle Asset Management has invested 0.02% in Monro, Inc. (NASDAQ:MNRO). Arlington Value accumulated 1.01 million shares or 4.84% of the stock. Point72 Asia (Hong Kong) reported 930 shares. Dimensional Fund Advsr Ltd Partnership reported 887,263 shares. Glenmede Company Na owns 0% invested in Monro, Inc. (NASDAQ:MNRO) for 2,705 shares. 6,978 are held by Envestnet Asset Mgmt Inc. Oppenheimer Asset Management stated it has 0.01% in Monro, Inc. (NASDAQ:MNRO). 7,030 are held by First Mercantile Tru Communications. Keybank Association Oh accumulated 11,940 shares or 0% of the stock. Nationwide Fund Advsr invested in 0.03% or 173,994 shares. Ameriprise Financial Inc reported 195,378 shares or 0% of all its holdings. State Board Of Administration Of Florida Retirement Sys has invested 0% in Monro, Inc. (NASDAQ:MNRO). Orrstown Financial Ser holds 0.03% in Monro, Inc. (NASDAQ:MNRO) or 636 shares. D E Shaw has invested 0% in Monro, Inc. (NASDAQ:MNRO). Wilen Mngmt has invested 0.12% in Monro, Inc. (NASDAQ:MNRO).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *